- Home
- GUTS vs IMUX Comparison
GUTS vs IMUX Comparison
Compare GUTS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- IMUX
- Stock Information
- Founded
- GUTS 2010
- IMUX 2016
- Country
- GUTS United States
- IMUX United States
- Employees
- GUTS N/A
- IMUX N/A
- Industry
- GUTS
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- IMUX Health Care
- Exchange
- GUTS NYSE
- IMUX Nasdaq
- Market Cap
- GUTS 58.8M
- IMUX 67.8M
- IPO Year
- GUTS 2024
- IMUX N/A
- Fundamental
- Price
- GUTS $1.60
- IMUX $0.70
- Analyst Decision
- GUTS Buy
- IMUX Strong Buy
- Analyst Count
- GUTS 1
- IMUX 6
- Target Price
- GUTS $10.00
- IMUX $11.60
- AVG Volume (30 Days)
- GUTS 916.8K
- IMUX 2.6M
- Earning Date
- GUTS 08-13-2025
- IMUX 08-07-2025
- Dividend Yield
- GUTS N/A
- IMUX N/A
- EPS Growth
- GUTS N/A
- IMUX N/A
- EPS
- GUTS N/A
- IMUX N/A
- Revenue
- GUTS $60,000.00
- IMUX N/A
- Revenue This Year
- GUTS N/A
- IMUX N/A
- Revenue Next Year
- GUTS N/A
- IMUX N/A
- P/E Ratio
- GUTS N/A
- IMUX N/A
- Revenue Growth
- GUTS N/A
- IMUX N/A
- 52 Week Low
- GUTS $0.87
- IMUX $0.56
- 52 Week High
- GUTS $4.92
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- GUTS 43.49
- IMUX 35.71
- Support Level
- GUTS $1.54
- IMUX $0.68
- Resistance Level
- GUTS $1.82
- IMUX $0.75
- Average True Range (ATR)
- GUTS 0.18
- IMUX 0.06
- MACD
- GUTS -0.07
- IMUX -0.00
- Stochastic Oscillator
- GUTS 10.13
- IMUX 10.40
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.